Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) FCF Margin (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed FCF Margin for 11 consecutive years, with 33.93% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 6427.0% to 33.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20.03% through Dec 2025, up 3332.0% year-over-year, with the annual reading at 20.03% for FY2025, 3665.0% up from the prior year.
  • FCF Margin for Q4 2025 was 33.93% at BeOne Medicines, up from 22.1% in the prior quarter.
  • The five-year high for FCF Margin was 33.93% in Q4 2025, with the low at 271.19% in Q2 2021.
  • Average FCF Margin over 5 years is 67.69%, with a median of 44.1% recorded in 2021.
  • The sharpest move saw FCF Margin skyrocketed 72122bps in 2021, then tumbled -11298bps in 2022.
  • Over 5 years, FCF Margin stood at 43.91% in 2021, then plummeted by -257bps to 156.89% in 2022, then soared by 32bps to 106.54% in 2023, then skyrocketed by 72bps to 30.34% in 2024, then skyrocketed by 212bps to 33.93% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 33.93%, 22.1%, and 19.93% for Q4 2025, Q3 2025, and Q2 2025 respectively.